Regulated protein aggregation: stress granules and neurodegeneration by Benjamin Wolozin
Wolozin Molecular Neurodegeneration 2012, 7:56
http://www.molecularneurodegeneration.com/content/7/1/56REVIEW Open AccessRegulated protein aggregation: stress granules
and neurodegeneration
Benjamin WolozinAbstract
The protein aggregation that occurs in neurodegenerative diseases is classically thought to occur as an undesirable,
nonfunctional byproduct of protein misfolding. This model contrasts with the biology of RNA binding proteins,
many of which are linked to neurodegenerative diseases. RNA binding proteins use protein aggregation as part of a
normal regulated, physiological mechanism controlling protein synthesis. The process of regulated protein
aggregation is most evident in formation of stress granules. Stress granules assemble when RNA binding proteins
aggregate through their glycine rich domains. Stress granules function to sequester, silence and/or degrade RNA
transcripts as part of a mechanism that adapts patterns of local RNA translation to facilitate the stress response.
Aggregation of RNA binding proteins is reversible and is tightly regulated through pathways, such as
phosphorylation of elongation initiation factor 2α. Microtubule associated protein tau also appears to regulate stress
granule formation. Conversely, stress granule formation stimulates pathological changes associated with tau. In this
review, I propose that the aggregation of many pathological, intracellular proteins, including TDP-43, FUS or tau,
proceeds through the stress granule pathway. Mutations in genes coding for stress granule associated proteins or
prolonged physiological stress, lead to enhanced stress granule formation, which accelerates the pathophysiology
of protein aggregation in neurodegenerative diseases. Over-active stress granule formation could act to sequester
functional RNA binding proteins and/or interfere with mRNA transport and translation, each of which might
potentiate neurodegeneration. The reversibility of the stress granule pathway also offers novel opportunities to
stimulate endogenous biochemical pathways to disaggregate these pathological stress granules, and perhaps delay
the progression of disease.
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The purpose of the review is to provide a new perspec-
tive on the role of protein aggregation in neurodege-
nerative disease. This perspective seeks to incorporate
the concept of regulated protein aggregation into the
pathophysiology of neurodegenerative diseases. High-
lighting the role of regulated protein aggregation in
disease pathology provides a biological context for
understanding how the process of pathological protein
aggregation in disease might evolve, identifies a broad
range of proteins that co-aggregate during disease (be-
yond the classic insoluble protein disease markers),Correspondence: bwolozin@bu.edu
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reproduction in any medium, provided the orilluminates signaling cascades regulating many of these
aggregation processes and provides potential pathways
for therapeutic intervention.
The classic model for pathological protein aggregation
in neurodegenerative diseases is based on mass action
and energy minimization, as elegantly proposed by
Dobson and Lansbury (Figure 1) [1,2]. In this model, ag-
gregation prone proteins are initially present in a cell as
monomers. Some of these proteins randomly misfold in
a process that is thought to be devoid of biological func-
tion. The misfolded proteins oligomerize, and aggregate
further to form fibrils. In each case, these processes are
thought to occur as undesirable, nonfunctional biological
events. The rate of aggregation of these proteins depends
on the amount of starting material (monomeric protein)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The conventional model for degenerative disease based on mass action and hydrophobic interactions. Monomeric proteins
randomly misfold. The chaperone system, including heat shock proteins (HSPs), can reverse the misfolding, and produce normal, functional
proteins. However, the misfolded proteins are prone to random oligomerization, and evidence suggests that the resulting oligomers can be toxic.
The oligomers aggregate further to form fibrillar aggregates. In each case formation of the misfolded proteins, oligomers and fibrils are
considered to lack normal biological functions. These oligomers and fibrillar aggregates can be removed by degradation, which occurs through
the actions of the autophagic system and the ubiquitin proteasomal system. Increasing evidence suggests that autophagy is the predominant
mechanism of degradation in diseases such as Alzheimer’s disease and Parkinson’s disease [3].
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starting material leads to more oligomerization by the
law of mass action. Greater hydrophobicity also increases
the propensity of a protein to oligomerize, due to a greater
the need for energy minimization of the hydrophobic
interactions. Oligomer and fibril accumulation are mini-
mized by the actions multiple protein chaperones, such as
heat shock proteins, as well as by actions of the ubiquitin
proteasomal and autophagic systems. Which act to de-
grade the accumulating oligomers and fibrils [3,4]. Despite
the elegant complexity of chaperones, the proteasomal
system and autophagy, the fundamental concept remains;
protein aggregation largely occurs as an unwanted che-
mical reaction driven by concentration gradients and
hydrophobicity. These unwanted oligomers and fibrils ap-
pear to cause toxicity, which elicits cell death and inflam-
mation. An example of the broader neurodegeneration
hypotheses is the amyloid cascade hypothesis, which links
all of this together in a recursive cycle [5].
RNA binding proteins: biology and contributions
to neurodegenerative diseases
The classical process of pathological protein aggregation
contrasts with the tightly regulated and reversible process
of aggregation that occurs as an intrinsic aspect of the bio-
logy of RNA binding proteins. RNA binding proteins have
gained attention recently because of the large number of
these proteins that are mutated in familial forms of motor
neuron diseases. Mutations in RNA binding proteins such
as Tar DNA binding protein-43 (TDP-43), Fused in sar-
coma (FUS), survival of motor neuron (SMN1), ataxin-2
(ATX2), optineurin (OPT) and angiogenenin (ANG) all
cause motor neuron diseases. The roughly 800 proteins inthis family exhibit conserved domains structures, and
related functions (Figure 2). These RNA binding proteins
generally contain two types of conserved domains: glycine
rich domains and RNA recognition motifs (RRM). The gly-
cine rich domain is hydrophobic and mediates the rever-
sible aggregation of these proteins; for some RNA binding
proteins, such as TIA-1, but not TDP-43, the glycine rich
domain shares homology with the yeast prion protein,
Sup35 (Figure 2); homology between Sup-35 and TDP-43
is much weaker [6,7]. The RRMs have broad specificity,
but differ in the spectrum of transcripts bound. For in-
stance, T-intracellular antigen-1 (TIA-1) recognizes tran-
scripts with a uracyl-rich motif with a 30–37 nucleotide
long bipartite motif [8]. TIA1 cytotoxic granule-associated
RNA binding protein-like 1 (TIAR) binds transcripts with
a 28–32 nucleotide long stem loop element [9]. The Hu
family of RNA binding proteins bind transcripts with a
17–20 nucleotide segment rich in uracyls [10].
The concept of reversible, regulated protein aggrega-
tion is central to the hypothesis proposed in this article
and demands clarification at the outset. The concept of
beneficial misfolding was perhaps first examined in
yeast, where the elongation initiation factor Sup35 was
shown to misfold in response to environmental (nutri-
tional) stress, and alter the synthesis of proteins in a
manner that promotes yeast survival [7]. Sup35 misfold-
ing is stable, is transmitted among yeast, and analogous
to the biology of prions [7]. Glycine rich domains in
Sup35 mediate the misfolding and also give rise to inso-
luble protein aggregates, much like amyloidogenic pro-
teins that aggregate in neurodegenerative diseases [13].
The homology between glycine rich domains of some
mammalian RNA binding proteins, such as TIA-1, and
Figure 2 Structures of RNA binding proteins. A) RNA binding proteins, such as TIA-1, TDP-43 and FUS, contain RNA-recognition motifs (RRM),
which bind RNA and Glycine rich (Gly-rich) domains that mediate protein aggregation. TDP-43 and FUS contain discrete nuclear localization and
nuclear export signals (NLS, NES), while nuclear localization of TIA-1 does not appear to localize to particular domains [11,12]. B) Alignment of
glycine rich domains of TIA-1, TIAR and Sup-35. The alignment was performed using the “multalin” program (http://multalin.toulouse.inra.fr). In the
consensus sequence, the red letters correspond to homologous amino acids, where the # symbol is used to convey imperfect homologies, and
the blue letters refer to partial homology.
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aggregation in the biology of RNA binding proteins
(Figure 2). The glycine rich domain of other RNA bind-
ing proteins, such as TDP-43, are not homologous to
Sup35, but are capable of interacting with Sup35, which
emphasizes the biological relatedness of these proteins
[14]. The response of many of these RNA binding pro-
teins to stress resembles that of Sup35 in that they ag-
gregate to form insoluble macromolecular structures,
composed of RNA binding proteins and mRNA, termed
stress granules (see below for further discussion of stress
granules) [15]. The resulting aggregates are detergent in-
soluble, and can be isolated through classic methods
used to isolate insoluble proteins aggregates present in
brain tissues of subjects with neurodegenerative diseases
[16,17].
The aggregation processes characterizing the biology
of Sup35 and RNA binding proteins differ from the con-
ventional models of protein aggregation in that they sub-
serve distinct biological functions and are reversible. In
order to understand how this biology plays out, it is im-
portant to examine the functions of RNA binding pro-
teins throughout the biological cycle of mRNA processing.
The functions of RNA binding proteins can generally be
divided into nuclear and cytoplasmic activities, each ofwhich is the subject of very large fields of literature. In the
nucleus RNA binding proteins regulate mRNA matu-
ration, including splicing, RNA helicase activity, RNA
polymerase elongation and nuclear export (Figure 3) [18].
In the cytoplasm RNA binding proteins regulate RNA
transport, silencing, translation and degradation (Figure 3)
[19]. These RNA binding proteins regulate transcript ac-
tivity and distribution by forming RNA granules that are
macromolecular complexes containing RNA binding pro-
teins and mRNA transcripts consolidated to form granules
through protein/protein interactions mediated by the
glycine rich domains and protein/mRNA interactions
mediated by RRMs [20]. RNA granules vary by molecular
composition and function. RNA degradation is mediated
by a type of RNA granule, termed the P-body [21]. Trans-
port granules play important roles in neurons, where they
move transcripts from the soma into the dendritic, and
axonal, arbors [20]. RNA binding protein complexes also
mediate the process of activity dependent protein synthe-
sis, which is critical in all aspects of biology, but has
attracted particularly strong attention at the synapse
where it controls synaptic plasticity, habituation and
memory [22]. The synaptic function of one RNA binding
protein, Fragile X mental retardation protein (FMRP) has
been studied extensively and is known to regulate
Figure 3 Structure and functions of RNA binding proteins. RNA binding proteins have dual sites of action. In the nucleus, many RNA binding
proteins, such as TDP-43, SMN (SMN1 and 2), TIA-1 and FUS regulate mRNA splicing. RNA binding proteins are also present in the cytoplasm and
neuronal arbors, where they regulate RNA transport, activity dependent protein synthesis and sequestration of unnecessary transcripts in
response to stress. Each of the RNA binding proteins shown in the figure associate with stress granules. TIA-1, SMN and Pumillio-2 are important
for trafficking of mRNA in axons and dendrites, which is mediated by microtubules (blue and mustard striped line) and molecular motors. At the
synapse, different RNA binding proteins regulate activity dependent translation. Phosphorylation causes 4E-BP to dissociate from eIF4E, which
initiates translation. FMRP inhibits this process; loss of FMRP expression (such as occurs in fragile X syndrome) leads to excessive synaptic protein
synthesis and excessive dendritic spine density. In contrast, CPEB stimulates activity dependent translation in a process that might involve
regulated protein aggregation [27]. Activity dependent protein synthesis is modulated by microRNA. For instance, miR125 regulates the synthesis
of mGluR and PSD-95 [24]. miRNA are generated by action of the RISC complex and argonaute, which cleave precursors to generate the miRs.
Adapted from Liu-Yesucevitz, et al. [10].
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interface with the micro-RNA system, since both micro-
RNA and RNA binding protein regulate protein synthesis
[25,26]. The interaction of microRNA with RNA binding
protein adds an additional layer of regulatory control.
Stress granules and regulated protein
aggregation
Stress granules (SGs) are another type of RNA granule
that is generated in response to stressful conditions.
Stressed cells need to produce cytoprotective proteins
quickly. This is accomplished by formation of SGs,
which shift RNA translation towards cytoprotective pro-
teins [28]. As mentioned above, SGs sequester and si-
lence non-essential transcripts, adapt local patterns of
translation within the cell and sequester signaling mole-
cules that regulate cell viability [19,29]. SGs also interact
with other types of RNA granules. SGs can be seenadjacent to P-bodies, putatively transferring transcripts
to the P bodies for degradation [30]. Neuronal transport
granules, which facilitate activity dependent translational
machinery at the synapse, can be converted to SGs.
Thus, RNA granules interact with each other and can
convert their functions depending on conditions.
The process of regulated protein aggregation that charac-
terizes SG formation and allows RNA binding proteins to
consolidate transcripts contrasts with vesicle formation,
which is the other major cellular mechanism for consolida-
ting molecules. Organelles such as the nucleus, mitochon-
dria, peroxisomes, lysosomes and endosomes consolidate
material by surrounding the concentrated target material
with one or two lipid membranes. However, regulated pro-
tein aggregation achieves molecular consolidation using a
process of reversible protein aggregation [31]. In cell cul-
ture, SGs form within minutes of a severe stress, and dis-
appear 1 – 3 hrs after the stress is removed [31].
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pathways mediated by phosphorylation of eIF2α. Stress-
ful conditions prompt phosphorylation of eIF2α at serine
51, which inhibits formation of a complex containing
eIF2, GTP and tRNAi
met [31]. Stress also induces trans-
location of many RNA binding proteins from the nu-
cleus to the cytoplasm. During stressful conditions,
capped mRNA remains bound to the pre-initiation com-
plex, which contains the other elongation factor binding
proteins EF-4A, E and G (Figure 4). This mRNA-protein
complex is bound by eIF3, poly-A and nucleating RNA
binding proteins, such as TIA-1, TIAR, tristetraprolin
(TTP) or GTPase activating protein binding protein
(G3BP), which bind the “naked” transcripts in the cyto-
plasm (Figure 4) [28]. The SGs are initially small, but in-
crease in size as the RNA binding proteins consolidate
by binding to each other through the glycine rich pro-
tein aggregation domains. This process of secondaryFigure 4 Mechanism of normal and pathological stress granule forma
specialized proteins from capped transcripts. The proteins eIF4A, E and G c
the ribosome (40S) as well as other translational regulators to synthesize pr
synthesis to begin. B) Stress leads to phosphorylation of eIF2α, dissociation
mRNA bound eIF4G and poly-A binding protein. Nucleating RNA binding p
which initiate stress granule formation. Once initiated, other RNA binding p
to increase the size and complexity of SGs. These SGs are rapidly reversible
cell biology by interacting with biological systems regulating apoptosis, sig
and tau, have a strong tendency to form oligomers, and then fibrils. The co
promote oligomerization by creating cellular domains with higher concent
oligomers and fibrils might serve as a nidus for SG formation, leading to ov
participates in this process because it mislocates to the soma and dendritic
stimulating SG formation [41]. Tau also directly binds RNA [42].maturation of SGs specifically containing G3BP is a
prominent cytoplasmic function of TDP-43 [32]. Muta-
tions in RNA binding proteins appear to increase their
propensity to aggregate and to form SGs. For instance,
disease-linked mutations of TDP-43, FUS and ataxin-2
promote aggregation, either by directly increasing the ten-
dency of the protein to aggregate, or (for many FUS muta-
tions) by preventing nuclear translocation [16,17,33-37].
The SG complex initially forms a structure that is concep-
tually analogous to a tree, with the glycine rich aggrega-
tion domains forming the core of the structure, and the
mRNA bound to the RRMI, hanging off the RNA binding
proteins. The complex of aggregated RNA binding pro-
teins grows with time as other RNA binding proteins are
recruited through binding to the associated transcripts
and binding to the protein aggregation domains of other
RNA binding proteins (Figure 4). Mature granules contain
many RNA binding proteins recruited after the initialtion. A) In normal, physiological conditions, neurons synthesize
omplex to form the eIF4F pre-initiation complex, which interacts with
oteins. Association with the 60S ribosome complex allows protein
of ribosomes and many of the translation initiation factors, leaving
roteins bind the free RNA and also form protein/protein complexes,
roteins bind to the mRNA and to the nucleating RNA binding proteins
upon removal of the stress, however prolonged SG formation affects
naling and RNA decay. C) Pathological proteins, such as TDP-43, FUS
nsolidation of RNA binding proteins during SG formation might
rations of these proteins. Conversely, the increased stability of
er-active SG formation. Microtubule associated protein tau also
arbor leading to interactions with SG proteins and potentially
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interactions and protein-RNA interactions presents an im-
portant methodological consideration for those investiga-
ting SG structure. Biochemical studies of RNA binding
protein associations in SGs require pretreatment with
RNAse to determine whether SG proteins are directly
associated or associated due to mutual binding to mRNA
transcripts [16]. Biochemical studies of SGs also demon-
strate that the RNA binding proteins present in SGs are
triton or SDS insoluble (depending on the protein studied,
and the conditions inducing the SG), which is analogous
to the biochemistry of proteins aggregates in many neuro-
degenerative diseases [6,16,17,28,31,38-40].
The importance of SGs for cytoprotection is high-
lighted by the effects of knockout of SG proteins, such
as TIA-1, or inhibition of eIF2α phosphorylation, which
render cells more vulnerable to acute stresses [43,44].
Conversely, inhibiting eIF2α dephosphorylation protects
against some forms of stress [45]. The actual mecha-
nisms by which SGs mediate protection, though, are
poorly understood. For instance, conditions of endoplas-
mic reticulum stress lead to formation of SGs that in-
hibit cytoplasmic RNA translation, while preferentially
retaining RNA translation in the endoplasmic reticulum
[46]. Global shifts in RNA translation or RNA degra-
dation are also observed with other stresses, with the
exact pattern of RNA translation or degradation varying
depending on the particular stress [47]. (The transla-
tional response of heat shock protein 70 (HSP70) to
stress is nuanced. HSP70 synthesis is stimulated by ex-
pression of the pro-aggregation prion domain of TIA-1,
but HSP70 synthesis is not stimulated by over-
expression of full length TIA-1 [6]. Although the HSP70
transcript contains capped mRNA, HSP70 synthesis does
not appear to occur preferentially during SG formation,
and might actually be inhibited [48]. On the other hand,
protein aggregation, such as those involved in degenera-
tive diseases, stimulates synthesis of HSP70. These
seeming contradictions highlight important areas of
HSP70 biology that are incompletely understood.) The
composition of SGs also varies greatly depending on the
type of stress. Since RNA binding proteins all exhibit dif-
ferent RNA binding profiles, the corresponding pattern
of RNA translation will vary with the stress. Thus, the
changes in RNA translation occurring with stress reflect
the biochemical cascades responding to the particular
stress, the location of SG formation within the cell, and
the pattern of RNA sequestration induced by the com-
position of the SGs.
Signaling regulates each step of the RNA maturation
cycle, including synthesis, splicing, formation of granules
(including stress granules), RNA granule transport and
activity dependent RNA translation. For instance, phos-
phorylation of the translation initiation factor, (eIF2α)silences translation and is regulated by four different
kinases: PERK, HRI, GCN2 and PKR. The regulation of
PERK activity has been perhaps the most intensively
studied, since PERK mediates stress of the endoplasmic
reticulum [49,50]. The SG response is classically
designed to cope with a transient stress, and rapidly
resolves after the stress is removed [31]. GADD34 is a
phosphatase that selectively dephosphorylates eIF2α
[51]. Dephosphorylating eIF2α disperses SGs and stimu-
lates RNA translation. SG formation is also regulated
through eIF2α-independent pathways such as cleavage
of tRNA by angiogenin or inhibition of ribosomal scan-
ning [52,53]. Signaling cascades such as mTOR, S6 kinase,
MAP kinases and Mnks regulate activity dependent trans-
lation [54]. The strong role that these signaling cascades
play in regulating SG formation demonstrates that RNA
translation generally, and SG formation specifically, are
both highly regulated processes. Thus, signaling cascades
regulate the process of RNA binding protein aggregation,
reversibly controlling SG formation or dissolution.
The process of SG formation and dispersion can also
be regulated by exogenous application of chemicals that
inhibit RNA translation. Cycloheximide and emetine in-
hibit SG formation by interfering with RNA translation
at the step of protein elongation in a manner that main-
tains the polysomes, which prevents free mRNA from
accumulating in the cytoplasm [15]. In contrast, puro-
mycin stimulates SG formation by causing premature
chain termination at the ribosome, inducing disassembly
of the polysome and producing free mRNA which are
then bound by RNA binding proteins [15]. These chemi-
cals are toxic, and thus not useful clinically, but com-
pounds such as salubrinal can induce SG formation
without much toxicity [45]. In addition, my laboratory is
currently studying novel compounds that inhibit SG for-
mation without toxicity.
The stress response is an integrated response, and this
integration also applies to SG production. The RNA
binding proteins, TIA-1, TIAR, TTP and G3BP nucleate
SGs; a full list of nucleating RNA binding proteins is
provided in other reviews, but these four RNA binding
proteins are the most commonly examined [29]. Matu-
ration of SGs leads to incorporation of multiple other
proteins that regulate other stress response systems.
Since SGs are designed to be transient, their formation
appears to inhibit irreversible cellular events, such as
apoptosis. The pro-apoptotic proteins RACK1, ROCK1
and TRAF2 are all sequestered in SGs, which inhibits
the apoptotic response [55,56]. Sequestered RACK1 is
unable to activate apoptosis mediated by MTK1, and
TRAF2 is unable to activate apoptosis mediated by
TNFα and NFκB. Binding of RSK2 and FAST kinase fur-
ther inhibit apoptosis, and also promotes translational
repression [57]. Signaling molecules, such as JNK,
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fold proteins known to regulate other signaling cascades,
such as AKAP350A and WDR62, which regulate the
responses to cAMP and oxidation, respectively [58,59].
Cytoskeletal machinery facilitates the coalescing of
RNA binding proteins to make the SG. Histone deacety-
lase 6 (HDAC6) is required for this process; it deacety-
lates tubulin to reduce microtubule-dependent motility,
which promotes consolidation of cellular complexes,
such as autophagosomes, aggresomes and mitochondria
targeted for mitophagy [60-62]. HDAC6 is also required
for SG formation [60]. Interestingly, microtubule asso-
ciated protein tau also regulates transport, classically
inhibiting anterograde transport. Stressful conditions
lead to tau phosphorylation and mislocalization to the
soma and dendrite, where it comes into contact with
RNA binding proteins associated with stress granules
[63]. Our recent results suggest that tau might modulate
SGs [38]. Tau biology is integrated with that of HDAC6,
which regulates its turnover [64]. Mutations in dynein
motor subunits, such as DLC2A, localize with SGs and
are required for SG formation, just as they are required
for other stress processes; these proteins couple SGs to
the cytoskeleton and facilitate consolidation into a local
region within the cell [60,65]. Dynactin subunit I and
profilin, both of which regulate actin filaments, cause fa-
milial ALS; since the SG protein TDP-43 accumulates in
ALS, it is tempting to speculate that these proteins also
regulate SG formation [66-68]. Not surprisingly, many of
the signaling cascades known to regulate HDAC6 and
molecular motors also regulate SG formation, including
JNK, MKK7 and rhoA [59,65,69]. This suggests the pre-
sence of a common group of proteins contributes to
consolidation of many of the structures occurring in re-
sponse to stress, such as SGs, autophagasomes and
aggresomes. The multiple different biological processes
that impact on SG formation further emphasizes that
the SGs are highly regulated and highly integrated into
the biological response to stress and RNA translation.
SGs co-localize with insoluble protein aggregates
in neurodegenerative diseases
The potential importance of SGs for neurodegenerative
disease becomes apparent because the process of SG for-
mation presents a biological pathway that could be vul-
nerable to the protein aggregates that accumulate in
neurodegenerative disease. RNA binding proteins are a
group of proteins that naturally form insoluble aggre-
gates, yet the aggregated material can disperse and reso-
lubilize [28]. RNA-protein SG complexes are sequestered
as SDS-soluble, but triton insoluble protein aggregates
[16]. Most, if not all, of the RNA binding protein linked to
neurodegenerative diseases associate with SGs in cell cul-
ture. TDP-43, FUS, ataxin-2, SMN, optineurin andangiogenin have all been shown to co-localize with classic
SG markers (TIA-1, TIAR and/or G3BP) in cells undergo-
ing stress [16,33,34,37,70]. SG proteins such as TIA-1,
eIF3 and poly-A binding protein, PABP also co-localize
with neuropathology in brain tissue of subjects with AD,
FTDP-17, FTLD-TDP and ALS, or animal models of these
diseases [16,38]. In addition, SMN, huntingtin and PrPsc
associate with SGs and modulate SG formation in cul-
tured cells [39,40,71]. Our studies of brain tissues from
animal models of tauopathy indicate that the solubility of
different SG proteins varies dramatically among particular
SG proteins. Biochemical fractionation of proteins from
these samples shows that RNA binding proteins such as
TIA-1, TTP and G3BP form aggregates that are triton in-
soluble but sarkosyl soluble [38]. In contrast, pathological
aggregates of tau or β-amyloid are highly insoluble [38].
Interestingly, TDP-43 and FUS also form highly insoluble
inclusions [16,34]. Thus the proteins that form the most
insoluble aggregates are those that have been shown to
cause familial forms of neurodegenerative disease, includ-
ing TDP-43, FUS and tau. Our studies (discussed below)
also point to a close link between tau and SG biology. Par-
kinson’s disease is perhaps the outlier, because α-synuclein
and Lewy bodies have not yet been associated with SG
biology, but leucine rich repeat kinase 2 (LRRK2) is
known to modulate RNA translation, which points to a
link with SG biology [72]. These results suggest that
disease-linked proteins form pathological aggregates that
are often, if not always, co-localized with SG proteins.
The examples of AD and FTLD-17 are particularly
striking because in both of these tauopathies, the load of
SG positive inclusions that form is large, exhibiting a
density that is equal to or greater than the load of
neurofibrillary tangles [38]. SG proteins such as TIA-1
and TTP identify most neurofibrillary tangles, but also
identify inclusions that appear to lack reactivity with anti-
bodies to phospho-tau (e.g., PHF-1 or CP13) or conforma-
tionally altered tau (e.g., Alz-50 or MC1). A different SG
protein, G3BP, identifies neurons that are predominantly
negative for pathological tau protein [38]. The abundance
of SGs in tauopathies suggests that the load of patho-
logical inclusions is much greater than would be apparent
by simply using markers of tau protein.
The co-localization of SGs with neuropathology in the
human brain suggests shared mechanisms. I propose
that the aggregation of pathological proteins (e.g., tau or
TDP-43) stimulates SG formation, and formation of SGs
accelerates aggregation of the pathological proteins
(Figure 4). As mentioned above, disease-linked patho-
logical proteins, such as tau and TDP-43, are known to
exhibit a tendency to form stable, insoluble protein
aggregates. The interaction between pathology of SGs is
easy to envision for RNA binding proteins that exhibit
disease-linked mutations, such as TDP-43, FUS,
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ALS. Disease linked mutations in these proteins increase
the tendency of the protein to aggregate. In addition, the
aggregates that form appear to be highly insoluble, highly
stable complexes. Since these proteins normally exist in
equilibrium between dispersed, soluble proteins and aggre-
gated, insoluble complexes; aggregation-accelerating muta-
tions would shift the equilibrium, leading to increased SG
formation and formation of the stable, long-lived protein
aggregates that we associate with disease pathology
(Figure 4). The presence of more aggregates and/or aggre-
gates with enhanced stability might also increase formation
of mature SGs around the aggregates, much like the nor-
mal evolution of SGs. This process of SG growth is analo-
gous to cross-seeding, and normally forms the basis of SG
maturation. Pathological cross-seeding already has been
shown in cell culture for polyglutamine rich proteins, such
as huntingtin, and for stimulation of tau aggregation by
α-synuclein [71,73]. This same process of accelerated
cross-seeding might occur in the brain for other patho-
logical proteins, more generally. The formation of long-
lived, stable insoluble protein aggregates could shift the
equilibrium of regulated protein aggregation towards
aggregation, leading to accelerated, long-lived SG forma-
tion (Figure 4). These highly insoluble aggregates could
also serve as a nidus for further aggregation of SGs, by
binding with other RNA binding proteins and also binding
RNA as part of the process of SG maturation. The result
would be an overactive SG pathway.
Overactive SG formation in tauopathies might seem
puzzling, since tau was not previously considered to be a
SG protein. However, our studies using transfected SH-
SY5Y cells demonstrate that SG formation stimulates
formation of phosphorylated tau inclusions [38]. Even
more strikingly, tau appears to stimulate SG formation
[38]. The latter result suggests that tau actually contri-
butes to the SG response, and might explain the strong
link between tauopathy and SGs. Evaluation of tau bio-
logy suggests a mechanism for interaction with SGs. Tau
expression is normally restricted to the axon, while the
RNA translation machinery is more abundant in the
soma and dendrites. However, stress stimulates tau
phosphorylation and mislocalization to the soma and
dendrite where it can interact with RNA binding pro-
teins, as well as RNA, associated with SGs [41,63]. This
interaction accelerates SG formation, and also might ac-
celerate tau aggregation. The mechanism remains to be
determined, but the building blocks underlying a puta-
tive mechanism are evident. Tau binds SG proteins, such
as TIA-1 and TTP, which provides for a direct inter-
action between tau and SGs [38]. In addition, RNA is a
known stimulus for tau aggregation in vitro [74], which
makes it possible that the RNA associated with SGs
might further promote tau aggregation. Thus, in the caseof tauopathies, aggregation of tau protein stimulates SG
formation, leading to enhanced SG formation, and SG
formation might stimulate tau aggregation.
Whether the overactive SG formation is good or bad
remains to be determined. The response of neurons to
SG formation might be analogous to the responses to
autophagy; some autophagy is needed for survival, but
too much autophagy can be deleterious. Neurons require
SGs for an effective stress response, but overactive,
overly stable SG complexes could easily interfere with
neuronal function by silencing transcripts and sequeste-
ring important proteins. Mutations associated with
disease-linked proteins increase the aggregation propen-
sity, which provides a direct mechanism for overactive
SG formation. Chronic stressful diseases or environmen-
tal conditions might also stimulate overactive SG forma-
tion. For instance, the oxidative stress associated with
aging, the trophic stress associated with diabetes or the
physical stress associated with chronic traumatic en-
cephalopathy all enhance SG formation creating the
conditions for pathological aggregation [75-77].
The effects of modulating the protein synthesis/SG
pathway were recently evaluated in an animal model of
Creutzfeld Jacob disease, where pathological misfolding
of PrP precipitates neurodegeneration. Mallucci and col-
leagues forced expression of GADD34 to reduce eIF2α
phosphorylation, inhibit SG formation and stimulate
protein synthesis [51]. This intervention reduced PrP-
induced neurodegeneration. In contrast, salubrinal, which
increases eIF2α phosphorylation, increased SG formation,
inhibited protein synthesis, and accelerated neurodege-
neration [51]. These results suggest that inhibiting the SG
pathway and stimulating protein synthesis can inhibit
PrP-mediated neurodegeneration. The discovery of over-
active SG formation in other diseases raises the possibility
that these pathways are over-active in multiple neurode-
generative diseases, and that pharmacotherapy targeting
SG formation might be neuroprotective.
Critical questions
SG biology provides a highly useful paradigm for under-
standing neurodegenerative diseases, but important
questions related to SG biology remain to be investi-
gated. The major questions can be divided into four
areas:
1.What are the consequences of stress granule
persistence? SGs are classically transient structures
but in neurodegenerative diseases they become
associated with pathological structures and appear to
persist. The biological consequences of this
persistence are not known. Persistent SGs might
protect the neuron by acting as a sink for
sequestering toxic oligomers. However, persistent
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binding proteins, which would interfere with their
normal function. In ALS, for instance, the pathology
is notable for the loss of nuclear TDP-43 and FUS. It
seems possible that these proteins might be absorbed
and sequestered by stable SGs. For instance, a recent
study compared the effects of TDP-43 and FUS
knockdown, and identified a discrete number of very
long, brain specific transcripts that are regulated in
common, including parkin and neurexin 3 [78].
Misregulation of these genes might contribute to
disease. Kinetics is another critical consideration. A
small group of nucleating RNA binding proteins
initiate SG formation, which then continue to grow
and incorporate other RNA binding proteins.
Persistence of SGs might allow other proteins to
interact with SGs, but with delayed kinetics. This
could lead to ubiquitination of SGs, interactions of
SGs with the autophagic system or dysfunction of
pro-apoptotic proteins [57].
2.Does translational repression contribute to the
pathophysiology of neurodegenerative diseases? The
role of the SG pathway in translational repression
also raises inherent questions about the role of
translation repression in the pathophysiology of
disease; the ability of GADD34 to delay progression
of PrP mediated degeneration emphasizes the
potential significance for therapy of
neurodegenerative diseases [51]. It seems likely that
as we understand how to manipulate this highly
regulated pathway, we will better understand the
biology of neurons and possibly gain insight into
pathways for intervention in neurodegenerative
diseases by modulating protein translation.
3.Do deficits in axonal and dendritic transport affect
stress granule biology? Multiple genes linked to
transport are genetically implicated in
neurodegenerative diseases. Since RNA transport
represents a large part of extra-nuclear function of
RNA binding proteins, it seems possible that the
pathophysiology of the transport biology might be
linked to the pathophysiology of RNA binding
proteins. Tau protein, which is a major component of
the pathology in AD and FTD, regulates microtubule
stability [41]. Mutations in transport proteins
profillin, kinensin, dynein and dynactin are all
associated with motor neuron diseases [66,79-81].
Whether these mutations affect transport of mRNA
to the synapse or SG formation remains an open
question.
4. α-Synuclein and Parkinson’s disease: Most of the
genes linked to Parkinson’s disease appear to be most
important to the biology of organelles and vesicles:
mitochondria, autophagy, mitophagy, lysosomalfunction and vesicular endocytosis [82]. The link
between Parkinson’s disease, RNA binding proteins
and regulated protein aggregation remains nebulous.
Some recent studies point to links with RNA
translation and regulated protein aggregation, but the
studies are small in number. Mutations in TDP-43
have been identified in some cases of PD [83]. TDP-
43 pathology is present in diffuse Lewy body disease,
which provides some support suggesting the
involvement of RNA binding proteins in
synucleinopathies, but no such pathology has been
reported for PD [84-86]. Some studies also implicate
RNA translation in the pathophysiology of PD.
Abeliovich’s group identified an association between
the length of the 3’ UTR of α-synuclein and
Parkinson’s disease [87]. Finally, LRRK2 is implicated
in the regulation of RNA translation [72]. Each of
these connections are interesting, but whether these
impact on the process of regulated protein
aggregation remains to be determined.
5.What are the pathways that regulate aggregation and
dis-aggregation? While some of the pathways
regulating SG formation are defined, it seems likely
that other pathways will be identified. In addition,
very little is known about the mechanisms that dis-
aggregate SGs. The ability of SGs to rapidly disperse
raises the specter of biochemical pathways that can
disperse (at least some) protein aggregates quicker
and more effectively than the classic pathways
known for HSPs, the ubiquitin proteasomal system
and autophagy. Identifying such pathways could be
particularly important in the context of
neurodegenerative diseases where SG formation
might be over active.
Conclusion
This review presents the concept of regulated protein
aggregation. The idea that protein aggregation might be
physiological and regulated presents a novel paradigm
for the field of neurodegenerative research. The classic
model of pathological protein aggregation is a process
that occurs through random interaction of misfolded
proteins. In this review, I point out that many of the
proteins linked to neurodegenerative disease assume a
conformation that favors aggregation as part of the nor-
mal biology of RNA granule formation generally, and SG
formation specifically. This physiological aggregation
becomes pathological when the pro-aggregation state is
favored because of mutations, other disease processes or
environmental conditions. Linkage of pathological pro-
tein aggregation to the normal biological process of
regulated protein aggregation is important because RNA
granule and SG formation are regulated by signaling cas-
cades and are reversible. The role of biochemical
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presents potentially novel targets for pharmacotherapy
of neurodegenerative disease.
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